Literature DB >> 23713780

Druggable orthosteric and allosteric hot spots to target protein-protein interactions.

Buyong Ma, Ruth Nussinov1.   

Abstract

Drug designing targeting protein-protein interactions is challenging. Because structural elucidation and computational analysis have revealed the importance of hot spot residues in stabilizing these interactions, there have been on-going efforts to develop drugs which bind the hot spots and out-compete the native protein partners. The question arises as to what are the key 'druggable' properties of hot spots in protein-protein interactions and whether these mimic the general hot spot definition. Identification of orthosteric (at the protein- protein interaction site) and allosteric (elsewhere) druggable hot spots is expected to help in discovering compounds that can more effectively modulate protein-protein interactions. For example, are there any other significant features beyond their location in pockets in the interface? The interactions of protein-protein hot spots are coupled with conformational dynamics of protein complexes. Currently increasing efforts focus on the allosteric drug discovery. Allosteric drugs bind away from the native binding site and can modulate the native interactions. We propose that identification of allosteric hot spots could similarly help in more effective allosteric drug discovery. While detection of allosteric hot spots is challenging, targeting drugs to these residues has the potential of greatly increasing the hot spot and protein druggability.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23713780      PMCID: PMC6361532          DOI: 10.2174/13816128113199990073

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  17 in total

1.  How an Inhibitor Bound to Subunit Interface Alters Triosephosphate Isomerase Dynamics.

Authors:  Zeynep Kurkcuoglu; Doga Findik; Ebru Demet Akten; Pemra Doruker
Journal:  Biophys J       Date:  2015-07-16       Impact factor: 4.033

2.  RMut: R package for a Boolean sensitivity analysis against various types of mutations.

Authors:  Hung-Cuong Trinh; Yung-Keun Kwon
Journal:  PLoS One       Date:  2019-03-19       Impact factor: 3.240

3.  Investigation of the interactions between the EphB2 receptor and SNEW peptide variants.

Authors:  Buyong Ma; Stephanie Kolb; Michael Diprima; Molleshree Karna; Giovanna Tosato; Qiqi Yang; Qiang Huang; Ruth Nussinov
Journal:  Growth Factors       Date:  2014-11-20       Impact factor: 2.511

4.  A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity.

Authors:  Jaime Abrego; Hannah Sanford-Crane; Chet Oon; Xu Xiao; Courtney B Betts; Duanchen Sun; Shanthi Nagarajan; Luis Diaz; Holly Sandborg; Sohinee Bhattacharyya; Zheng Xia; Lisa M Coussens; Peter Tontonoz; Mara H Sherman
Journal:  Cancer Discov       Date:  2022-10-05       Impact factor: 38.272

5.  Implications of the Essential Role of Small Molecule Ligand Binding Pockets in Protein-Protein Interactions.

Authors:  Jeffrey Skolnick; Hongyi Zhou
Journal:  J Phys Chem B       Date:  2022-08-31       Impact factor: 3.466

Review 6.  Adaptability of protein structures to enable functional interactions and evolutionary implications.

Authors:  Turkan Haliloglu; Ivet Bahar
Journal:  Curr Opin Struct Biol       Date:  2015-08-06       Impact factor: 6.809

7.  A structural study of the complex between neuroepithelial cell transforming gene 1 (Net1) and RhoA reveals a potential anticancer drug hot spot.

Authors:  Alain-Pierre Petit; Christel Garcia-Petit; Juan A Bueren-Calabuig; Laurent M Vuillard; Gilles Ferry; Jean A Boutin
Journal:  J Biol Chem       Date:  2018-04-25       Impact factor: 5.157

8.  In Silico Insights towards the Identification of SARS-CoV-2 NSP13 Helicase Druggable Pockets.

Authors:  Federico Ricci; Rosaria Gitto; Giovanna Pitasi; Laura De Luca
Journal:  Biomolecules       Date:  2022-03-22

Review 9.  Drug-Like Protein-Protein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology.

Authors:  Bruno O Villoutreix; Melaine A Kuenemann; Jean-Luc Poyet; Heriberto Bruzzoni-Giovanelli; Céline Labbé; David Lagorce; Olivier Sperandio; Maria A Miteva
Journal:  Mol Inform       Date:  2014-06-02       Impact factor: 3.353

10.  Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem.

Authors:  Lei Xie; Philip E Bourne
Journal:  Front Pharmacol       Date:  2015-09-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.